Date: July 20th, 2022 – 6:00-7:00 PM ET* (watch the recorded webinar)
Join us as we learn about the basics of DCM genetics and the future of DCM gene therapy. This promises to be a very interesting and informative event for all DCM patients and their family members.
- Basics of DCM Genetics
- What is Gene Therapy
- How is Gene Therapy Manufactured
- The Future of DCM Gene Therapy
- Live Q&A
Date: Wed., July 20th, 2022
Time: 6:00-7:00 PM ET
Please share the details of this webinar with individuals impacted by DCM and their families.
Kee-Hong Kim, Ph.D.
Chief Technology Officer
Dr. Kim joined Tenaya in 2018 to serve as Senior Vice President of Technical Operations. During his tenure, he has led the company’s effort to internalize process development, analytical development and quality control capabilities, and overseen the establishment of Tenaya’s cGMP manufacturing facility. Prior to joining Tenaya, Dr. Kim was Senior Vice President, Head of Technical Operations at Agilis Biotherapeutics, where he had accountability for manufacturing of gene therapy drug products and establishing reliable clinical and commercial supply chains.
Prior to that, he was the Head of Gene Therapy Process Development and the Global CMC Lead of Gene Therapy at Shire. Dr. Kim also ran his own biopharma consulting firm, which he started after serving as Director of Process Development at Avalanche Biotechnology (now Adverum). Dr. Kim was responsible for the process development, manufacturing science and related regulatory filings for Dendreon’s commercial product PROVENGE™. Earlier in his career, Dr. Kim had roles of increasing leadership at several technical organizations including Aeras TB Foundation and Walter Reed Army Medical Center. He completed his post-doctoral training at Cornell University and received his doctoral degree in chemical engineering from Colorado State University.
Executive Director, Clinical Site Head
Scott has 27 years of experience in the pharmaceutical and biotechnology field specializing in the design, construction, automation and validation of production facilities. Scott has developed and maintained programs for engineering project delivery, equipment acquisition, and commissioning & qualification.
Prior to Joining Tenaya, Scott served as Senior Director of Technical Operations at Novartis Gene Therapies where he executed major capital projects to design and construct manufacturing, laboratories, warehousing and office complexes for cutting-edge gene therapy manufacturing technologies and modular facility design. Scott’s areas of expertise include building manufacturing, quality control, facility and engineering organizations, applying solid engineering principles to complex processes in the bio tech and gene therapy space
Date: July 20th, 2022 – 6:00-7:00 PM ET*
*Note: All webinar registrants will receive a link to access the recording after the live event.